IAS 2019: late breaker highlights to look for

17 July 2019. Related: Conference reports, Antiretrovirals.

Simon Collins, HIV i-Base

IAS 2019 has already highlighted important late-breaking studies for the upcoming conference.

These include:

• New data on the possible risk of birth defects with dolutegravir (DTG)-based HIV treatment during pregnancy from Botswana and Brazil.
• Results of the first human trial of a new PrEP implant.
• A study of same-day PrEP initiation for men who have sex with men in Brazil Mexico and Peru.
• New insights from the DISCOVER trial comparing F/TAF and F/TDF as PrEP.
• Analyses of the need for integrated HIV and sexual and reproductive health care from the recently completed ECHO trial examining HIV and STI incidence, PrEP use and contraceptive effectiveness among young women at high risk.
• Results of the phase 2a ASCENT study of mosaic-based vaccines.
• Latest data on effectiveness of two-drug DTG/3TC regimens for HIV treatment.
• ADVANCE study results on the use of DTG- and TAF-based treatment regimens in sub-Saharan Africa.
• New efficacy data on the novel drug MK-8591 for HIV treatment.

The programme for this conference is now online.
http://www.ias2019.org